Recent Press Releases

Abbott Hosts Conference Call for Second-Quarter Earnings

ABBOTT PARK, Ill., July 1, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2015 financial results on

Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement

INDIANAPOLIS, July 1, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial resu

TUMS® Celebrates American Barbecue

Presents TUMS® BBQ Fan Content; Embarks on Nationwide Tour in Search of '#TUMSworthy' Summer Foods


New Jersey's Hart and Celgene and Johnson & Johnson Executives Named to Scientific American Worldview 100 Most Influential People in Biotechnology

Trenton, NJ (June 18, 2015) - BioNJ President and CEO Debbie Hart, along with five other New Jersey executives, including Bob Hugin, Chairman and CEO, Celgene; Sol Barer, Ph.D., Founder, Celgene, and...


30 June 2015 AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years...

New Indication for Teijin Pharma's Febuxostat in Europe

Tokyo, Japan, June 30, 2015 --- Teijin Pharma Limited, the core company of the Teijin Group's medical and pharmaceutical business, announced today, the Menarini Group, a sublicensee of its European...

Global Biosimilars Market Value Could Hit $55 Billion by 2020, says GBI Research

NEW YORK (GBI Research), 30 June 2015 The global biosimilars market value is expected to reach $20 billion by the end of 2015 and could hit $55 billion by 2020, with growth primarily driven by a...

Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma

INDIANAPOLIS and OXFORD, England, June 29, 2015 /PRNewswire/ -- Eli Lil

AbbVie to Expand its Medical Device Operation in Sligo

Creation of 50 new jobs and investment of €40 million over 4 years Sligo 29th June 2015 –Minister for Jobs, Enterprise and Innovation Richard Bruton TD, today announced that AbbVie (ABBV:...

Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Union

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU

First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU Farydak shown to slow progression of rare blood cancer The European Medicines Agency (EMA) has recommended...

EYLEA® (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion

TARRYTOWN, N.Y., June 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval...

BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping SAN RAFAEL, Calif., June 25, 2015 (GLOBE NEWSWIRE) -- BioMarin...

UK Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit

INDIANAPOLIS, June 25, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the C

Veracyte Announces National Network Agreement with Aetna

SOUTH SAN FRANCISCO, Calif., June 25, 2015 /PRNewswire/ -- 

Diabetes Scholars Foundation Announces 2015 Scholarship Recipients

Lilly Diabetes donation helps 21 students attend college through Tomorrow's Leaders Scholarships


Class Action Alleges Novartis Gleevec Patent Infringement Suit a Sham

Complaint seeks permanent injunctive relief to prevent overcharges and damages, and bring generic Gleevec to market BOSTON – A class-action lawsuit filed against Novartis alleges that the...

Novartis statement on Gleevec patent lawsuit

"We believe these claims are unsubstantiated. The patents covering Gleevec remain legally in force and are covered by a statutory presumption of validity. The patents are clearly directed to...

FDA Drug Safety Communication: FDA reporting permanent skin color changes associated with use of Daytrana patch (methylphenidate transdermal system) for treating ADHD

The U.S. Food and Drug Administration (FDA) is warning that permanent loss of skin color may occur with use of the Daytrana patch (methylphenidate transdermal system) for Attention Deficit...